NanoViricides, Inc. NEW (NNVC) News

NanoViricides, Inc. NEW (NNVC): $1.45

-0.08 (-5.47%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NNVC to Watchlist
Sign Up

Industry: Biotech


Ranked

of 454

in industry

Filter NNVC News Items

NNVC News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

NNVC News Highlights

  • For NNVC, its 30 day story count is now at 2.
  • Over the past 20 days, the trend for NNVC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about NNVC are TALK.

Latest NNVC News From Around the Web

Below are the latest news stories about NANOVIRICIDES INC that investors may wish to consider to help them evaluate NNVC as an investment opportunity.

NanoViricides, Inc. to Present at the RHK Capital Disruptive Growth Conference in New York City on December 6th at 1:20pm ET

NanoViricides, Inc. (NYSE Amer. NNVC) (the "Company"), announces that the Company's President, Dr. Anil Diwan, will be presenting a talk at the RHK Capital Disruptive Growth Conference in New York City on December 6th at 1:20pm ET.

Yahoo | December 5, 2022

NanoViricides, Inc. Has Filed its Quarterly Report: Coronavirus Drug NV-CoV-2 IND Stage

NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal first quarter ending September 30, 2022 with the Securities and Exchange Commission (SEC) on Monday, November 14, 2022.

Yahoo | November 15, 2022

7 Speculative Penny Stocks Under $3 That Deserve Your Attention in Nov.

Speculative penny stocks don't look as volatile now that volatility is unavoidable.

Alex Sirois on InvestorPlace | October 28, 2022

This Company Is Looking For A Monkeypox Drug As City Investigates Deaths

By David Willey, Benzinga

Yahoo | October 27, 2022

NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug NV-CoV-2 IND Stage

NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2022 with the Securities and Exchange Commission (SEC) on Thursday, October 13, 2022.

Yahoo | October 14, 2022

NanoViricides Reports Its Novel Monkeypox Antiviral Could Reach Clinical Status Rapidly

By Rachael Green, Benzinga

Yahoo | September 19, 2022

Monkeypox Is Popping Up In Places It Shouldn’t But NanoViricides Says It May Have A Solution

Benzinga - Rachel Green

Yahoo | August 10, 2022

NanoViricides Provides Additional Details on Its Rapid Monkeypox Drug Strategy

NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, provides further details on its rapid drug development strategy for Monkeypox virus.

Yahoo | August 9, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning!

William White on InvestorPlace | August 4, 2022

NanoViricides Reports That It Has Begun Drug Development to Combat Monkeypox Virus

NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, reports that it has begun drug development to combat the monkeypox virus.

Yahoo | August 4, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5742 seconds.